55. The process of any one of claims 35 to 54 wherein the step of solvent extraction is conducted at least partially concurrently with the step of aging whereby the steps of aging and solvent removal are for sufficient time to allow for at least partial separation of the first polymer and the second polymer within droplets of the emulsion so as to form a core comprising the first polymer and a shell surrounding the core and comprising the first polymer and the second polymer, wherein the first polymer forms a plurality of continuous pathways through the shell.

56. The process of any one of claims 35 to 55 wherein the first and second solvents are partially miscible with the aqueous liquid and the step of removing the solvent(s) comprises diluting the particulate substance as aqueous suspension with the aqueous liquid which has neither the first nor the second solvent therein.

57. The process of any one of claims 35 to 56 comprising separating the particulate substance from the aqueous liquid.

58. The process of claim 57 comprising heating the separated particulate substance in a mold for sufficient time and at sufficient temperature to cause the microparticles to adhere together so as to form pellets of the particulate substance.

59. The process of claim 58 wherein the sufficient temperature which is the glass transition temperature of the second polymer or is above said temperature.

60. The process of claim 58 or claim 59 wherein the first solution comprises a releasable material and the sufficient temperature is below the temperature at which said releasable material degrades over the sufficient time.

61. A method for delivering a material to a liquid comprising exposing a substance according to claim 1 to said liquid in the presence of a degrading agent which is capable of degrading the first polymer, said substance being one in which the cores of the microparticles contain the material.

62. The method of claim 61 wherein the liquid is, or comprises, the degrading agent.

63. The method of claim 61 or claim 62 which is for a non-therapeutic, non-diagnostic purpose.

64. The method of claim 61 or claim 62 wherein the material is a therapeutic substance and the liquid is a bodily fluid, whereby the method is for delivering the therapeutic substance to a patient.

65. The method of claim 64 wherein the patient is a non-human.

66. The method of any one of claims 61 to 6566 wherein the microparticles of the substance are adhered together.

67. Use of a substance according to claim 13 infor the manufacture of a medicament for the treatment of a condition in a patient, optionally a non-human patient, wherein the releasable material is indicated for treatment of said condition.

68. The ~~Use~~ use according to claim 67, wherein the condition is pain and the releasable material is an analgesic.

69. The ~~Use~~ use of a substance according to claim 67 wherein the condition is glaucoma, wherein the releasable material is indicated for treatment of glaucoma.

70. The ~~Use~~ use according to claim 69 wherein the releasable material is brimonidine tartarate.

71. The ~~Use~~ use according to claim 67 wherein the releasable material is an antifibrotic agent.

72. The ~~Use~~ use according to claim 71 wherein the antifibrotic agent is fluorouracil.

73. The substance according to claim 13 for use in therapy.